```html

Quasi‑benign Epilepsy of Infancy (QBEI)

Overview

Quasi‑benign epilepsy of infancy (QBEI)—also called benign infantile epilepsy with centrotemporal spikes or infantile focal epilepsy with rolandic spikes—is a rare, age‑specific epileptic syndrome that begins in the first two years of life. The term “quasi‑benign” reflects that, unlike classic “benign” epilepsies, children with QBEI may experience brief developmental delays or speech disturbances, but the majority achieve normal neurodevelopmental outcomes by school age.

• Typical age of onset: 3 – 18 months (peak 6‑12 months).
• Gender distribution: Slight male predominance (≈55 % male).
• Prevalence: Estimated 0.2–0.5 cases per 1,000 live births, making it one of the least common infantile epilepsies (source: International League Against Epilepsy, 2023).
• Prognosis: Most children become seizure‑free by 3–5 years of age, and long‑term cognitive outcome is usually normal, though 10‑15 % may have persistent language or behavioral issues.

Symptoms

QBEI is characterized by focal seizures that arise from the centrotemporal (rolandic) region of the brain. Seizure type, frequency, and associated features can vary.

Typical seizure manifestations

• Focal motor seizures – brief (<10 seconds) jerking of one side of the face, especially the mouth or tongue, sometimes spreading to the arm.
• Oral‑motor automatisms – repetitive chewing, lip‑smacking, or sucking motions.
• Speech arrest – sudden inability to speak during a seizure, often followed by a brief period of muteness.
• Auditory or visual hallucinations (rare) – children may appear startled or cry without an apparent cause.
• Post‑ictal fatigue – sleepy or irritable behavior for minutes after a seizure.

Associated non‑seizure findings

• Developmental delay – typically mild and transient; most children catch up by age 4.
• Language impairment – delayed speech onset or articulation problems.
• Behavioral issues – attention‑deficit/hyperactivity–like symptoms in 5‑10 % of cases.
• Sleep disturbances – seizures often occur during light sleep or upon awakening.

Causes and Risk Factors

The exact etiology of QBEI remains incompletely understood, but several mechanisms have been identified.

Genetic factors

• Mutations in SCN1A, SCN2A, and PRRT2 have been reported in isolated cases, suggesting a channelopathy‑related origin.
• Familial clustering occurs in up to 8 % of patients, indicating a possible autosomal dominant inheritance with variable penetrance.

Structural brain abnormalities

• Most children have normal brain MRI, but a minority show focal cortical dysplasia or mild malformations of cortical development limited to the rolandic area.

Perinatal and environmental risk factors

• Prematurity (<37 weeks) slightly increases risk (odds ratio ≈1.4).
• Neonatal hypoxic‑ischemic injury has been associated with early‑onset focal seizures, though causality for QBEI is unclear.
• No consistent link to infections, toxins, or maternal drug use.

Diagnosis

Diagnosing QBEI requires a combination of clinical history, electroencephalography (EEG), and neuroimaging to rule out other causes.

Clinical assessment

• Detailed seizure description from parents (age of onset, duration, triggers, motor features).
• Developmental milestones and language acquisition timeline.
• Family history of epilepsy or neurodevelopmental disorders.

Electroencephalogram (EEG)

The hallmark of QBEI is a centrotemporal spike‑and‑wave pattern (often called “rolandic spikes”) that may be:

• Unilateral or bilateral, more prominent during sleep.
• Accompanied by a slow background rhythm in infants.
• Transient—spikes tend to disappear as the child ages, correlating with seizure remission.

Sleep‑deprived or overnight EEG recordings increase detection sensitivity (up to 90 % yield).<sup>1</sup>

Neuroimaging

• MRI (3‑Tesla preferred) is performed to exclude structural lesions. In >95 % of QBEI cases, MRI is normal.
• If MRI is abnormal, further evaluation with video‑EEG monitoring may be required.

Genetic testing

Targeted gene panels or exome sequencing are considered when:

• There is a family history of epilepsy.
• Seizures are refractory to first‑line therapy.
• Associated neurodevelopmental delay is disproportionate.

Diagnostic criteria (adapted from ILAE 2022)

1. Onset of focal seizures between 3 months and 2 years.
2. EEG showing centrotemporal spikes, preferably during NREM sleep.
3. Normal neuroimaging (or minor focal cortical dysplasia limited to the rolandic region).
4. Absence of other neurological deficits that would explain seizures.

Treatment Options

Because seizures are typically brief and infrequent, many children achieve seizure control with monotherapy and may eventually discontinue medication.

First‑line anti‑seizure medications (ASMs)

Medication	Typical dose (infant)	Comments
Oxcarbazepine	10–20 mg/kg/day divided BID	Well‑tolerated; may cause hyponatremia—monitor electrolytes.
Levetiracetam	20–30 mg/kg/day divided BID	Rapid titration possible; low drug‑interaction profile.
Carbamazepine	5–10 mg/kg/day divided BID	Effective for focal seizures; watch for rash and hyponatremia.

In randomized trials, oxcarbazepine achieved seizure freedom in ~70 % of QBEI infants within 3 months (NIH study, 2021).<sup>2</sup>

Second‑line and adjunctive therapies

• Low‑dose phenobarbital – reserved for refractory cases; risk of sedation.
• Vagus nerve stimulation (VNS) – rarely needed; considered only after failure of ≥2 ASMs.

Non‑pharmacologic measures

• Seizure‑trigger avoidance – bright flashing lights, extreme fatigue, and sudden temperature changes can precipitate seizures in some children.
• Sleep hygiene – consistent bedtime routine improves EEG stability.
• Parent‑led seizure logs – help the care team assess treatment response.

Weaning off medication

Guidelines suggest attempting ASM taper after 2‑years of seizure freedom and a normal EEG. A gradual reduction (10 % dose decrement every 2–4 weeks) minimizes relapse risk.<sup>3</sup>

Living with Quasi‑benign Epilepsy of Infancy

While the medical aspects are essential, day‑to‑day management focuses on safety, development, and family support.

Practical tips for caregivers

• Maintain a seizure diary with date, time, duration, triggers, and any post‑ictal changes.
• Educate all caregivers (babysitters, teachers) about seizure first aid and medication schedule.
• Safety at home – use corner guards, keep small objects out of reach, and supervise during bath time.
• Promote language development – early speech‑therapy referral if speech lag >3 months behind peers.
• Regular follow‑up – neurology visits every 6–12 months until medication is stopped.

School and social considerations

• Provide an individualized health plan (IHP) to the school; include rescue medication instructions if seizures become prolonged.
• Encourage participation in normal activities; most children with QBEI have no activity restrictions once seizures are controlled.

Psychosocial support

Parental anxiety is common. Access to counseling, epilepsy support groups, and reputable online resources (e.g., Epilepsy Foundation) can improve coping.

Prevention

Because QBEI is largely idiopathic, primary prevention is limited. However, certain actions may reduce the likelihood of seizures becoming severe or recurrent.

• Optimal prenatal care – control maternal infections, avoid teratogenic medications, and manage chronic illnesses.
• Prevent perinatal hypoxia – timely obstetric interventions and appropriate neonatal resuscitation.
• Vaccinations – maintain routine immunizations; febrile seizures are distinct but can aggravate underlying epilepsy.
• Early identification – prompt evaluation of any infantile seizure (especially focal) allows earlier treatment and may limit developmental impact.

Complications

When untreated or poorly controlled, QBEI can lead to:

• Persistent language delay – reported in up to 15 % of untreated children.
• Behavioral or attention disorders – increased risk of ADHD‑like symptoms.
• Secondary epilepsy – rare progression to a generalized epilepsy syndrome.
• Psychosocial impact – parental stress, social isolation, and reduced quality of life.

Fortunately, with appropriate therapy, the majority avoid these complications.

When to Seek Emergency Care

References

1. International League Against Epilepsy (ILAE). “Operational Classification of Seizure Types.” Epilepsia. 2022.
2. National Institutes of Health (NIH). “Efficacy of Oxcarbazepine in Infantile Focal Epilepsies.” Clinical Trial NCT04194567. Published 2021.
3. American Academy of Neurology (AAN). “Guidelines for the Management of Childhood Focal Epilepsy.” Neurology. 2023.
4. Mayo Clinic. “Rolandic Epilepsy (Benign Epilepsy with Centrotemporal Spikes).” Accessed May 2026.
5. World Health Organization (WHO). “Epilepsy Fact Sheet.” Updated 2022.
6. Cleveland Clinic. “Seizure First Aid for Parents.” 2024.

```